In summary, our research demonstrated that IL‐17A promotes the invasion–metastasis cascade by activating the AKT pathway and provides a rationale for the combination of secukinumab and sorafenib in advanced HCC treatment. This evidence concerns the gene IL17A and hepatocellular carcinoma.